StreetInsider.com News Articles

William Blair Starts Cytokinetics (CYTK) at Outperform

Thu, 15 Oct 2026 16:50:50 -0400

William Blair analyst Alethia Young initiates coverage on Cytokinetics (NASDAQ: CYTK) with a Outperform rating.

The analyst comments "We are initiating coverage of Cytokinetics with an Outperform rating, and our DCF-based valuation is $101/share. Cytokinetics is a commercial-stage specialty cardiology company built around muscle biology and its first approved product, MYQORZO. Our CYTK call: We have conviction in a strong MYQORZO launch through 2027. Around mid-2027, we model nHCM approval, assuming priority review, adding ~100K addressable patients. We estimate 2032 sales of ~$3.74B. Key risks are MYQORZO commercial launch, regulatory, and clinical execution."

For an analyst ratings summary and ratings history on

William Blair Starts Cytokinetics (CYTK) at Outperform

Thu, 15 Oct 2026 16:50:50 -0400

William Blair analyst Alethia Young initiates coverage on Cytokinetics (NASDAQ: CYTK) with a Outperform rating.

For an analyst ratings summary and ratings history on

Cytokinetics (CYTK) PT Lowered to $104 at UBS

Wed, 14 Oct 2026 06:51:52 -0400

UBS analyst Ashwani Verma lowered the price target on Cytokinetics (NASDAQ: CYTK) to $104.00 (from $115.00) while maintaining a Buy rating.

The analyst comments "We see CYTK as an attractive launch name (oHCM) that has the added benefit of diversification (nHCM) and potential removal of competitive overhang (EWTX). Similar to a number of other commercial biotech names (NBIX, AXSM, JAZZ, UTHR, INSM), CYTK has also underperformed recently as XBI pulled back. However, if interest-rate hike cycle is likely to drive further "risk-off" environment, we believe names like CYTK can outperform from current levels. In our view, Myqorzo will see continued sales

Cytokinetics (CYTK) PT Lowered to $104 at UBS

Wed, 14 Oct 2026 06:51:52 -0400

UBS analyst Ashwani Verma lowered the price target on Cytokinetics (NASDAQ: CYTK) to $104.00 (from $115.00) while maintaining a Buy rating.

Form 4 CYTOKINETICS INC For: Oct 12 Filed by: Blum Robert I

Tue, 13 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261013/27181002.html

Form 144 CYTOKINETICS INC Filed by: Blum Robert I

Tue, 13 Oct 2026 08:20:00 -0400

si-local-file:///var/storage/secattach/20261013/27177680.html

Cytokinetics shares new aficamten data for non-obstructive HCM

Mon, 12 Oct 2026 16:03:15 -0400

Cytokinetics, Incorporated (Nasdaq: CYTK) presented additional data from its ACACIA-HCM clinical trial at the Heart Failure Society of America Annual Scientific Meeting 2026 in Phoenix, Arizona, according to a company press release.

The data covered three areas: comprehensive exercise performance, a global efficacy responder analysis, and dose titration and safety. In the exercise performance analysis, treatment with aficamten significantly improved scores on the Boston Exercise Aggregate Physiologic Response Score at 36 weeks compared to placebo (p<0.001), with gains across all five measured domains. Score improvements correlated with health status measures and the cardiac biomarker NT-proBNP.

In the responder analysis, 53% of patients

Cytokinetics shares new aficamten data for non-obstructive HCM

Mon, 12 Oct 2026 16:03:15 -0400

In the responder analysis, 53% of patients

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Mon, 12 Oct 2026 16:00:00 -0400

Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, AZ.

“These additional analyses from ACACIA-HCM add to the body of evidence supporting the overall benefit-risk profile of aficamten in patients with nHCM,” said

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Mon, 12 Oct 2026 16:00:00 -0400

Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM

“These additional analyses from ACACIA-HCM add to the body of evidence supporting the overall benefit-risk profile of aficamten in patients with nHCM,” said

Cytokinetics (CYTK) PT Raised to $113 at RBC Capital

Thu, 08 Oct 2026 08:27:13 -0400

RBC Capital analyst Leonid Timashev raised the price target on Cytokinetics (NASDAQ: CYTK) to $113.00 (from $112.00) while maintaining a Outperform rating.

Form 4 CYTOKINETICS INC For: Oct 06 Filed by: Malik Fady Ibraham

Tue, 06 Oct 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20261006/27155854.html

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

Fri, 02 Oct 2026 07:30:00 -0400

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.

Late-Breaking Clinical Trial Presentations

Title: Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results from ACACIA-HCM
Presenter: Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital & Medical Center; and National Principal Investigator of SEQUOIA-HCM
Date: Monday, October 12, 2026
Session Title: Monday Plenary Session:

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

Fri, 02 Oct 2026 07:30:00 -0400

Late-Breaking Clinical Trial Presentations

Cytokinetics launches real-world study of aficamten in heart disease

Wed, 30 Sep 2026 07:31:53 -0400

Cytokinetics, Incorporated (Nasdaq: CYTK) announced the launch of ASPEN-HCM, a prospective, multicenter, observational real-world study evaluating its cardiac drug MYQORZO (aficamten) in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), according to a press release.

Led by the University of California, San Francisco, the study will span 13 cardiology practices and HCM centers of excellence, aiming to enroll approximately 400 patients over an anticipated 12-to-36-month period. The study will assess the real-world safety profile, clinical effectiveness, and economic impact of MYQORZO in routine clinical practice.

Key endpoints include reductions in left ventricular ejection fraction, treatment discontinuations, changes in left ventricular outflow tract

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Wed, 30 Sep 2026 07:30:00 -0400

Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of ASPEN-HCM (Aficamten Study of Patient Experience and Novel Outcomes in Symptomatic Obstructive HCM), a prospective, multicenter, observational real-world study evaluating MYQORZO® (aficamten) in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Wed, 30 Sep 2026 07:30:00 -0400

Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice

Form 4 CYTOKINETICS INC For: Sep 28 Filed by: Blum Robert I

Mon, 28 Sep 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260928/27115277.html

Form 4 CYTOKINETICS INC For: Sep 22 Filed by: Malik Fady Ibraham

Tue, 22 Sep 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20260922/27092081.html

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 17 Sep 2026 16:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of common stock and 35,025 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 23 employees, whose employment commenced in August and September 2026 as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 17 Sep 2026 16:00:00 -0400

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of

Form 144 CYTOKINETICS INC Filed by: Blum Robert I

Tue, 15 Sep 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260915/27065971.html

Form 4 CYTOKINETICS INC For: Sep 15 Filed by: Landry Robert E

Tue, 15 Sep 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260915/27065886.html

Form 4 CYTOKINETICS INC For: Sep 14 Filed by: Blum Robert I

Tue, 15 Sep 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260915/27065869.html

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program

Mon, 14 Sep 2026 07:30:00 -0400

Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases

Deadline for Applications is October 2, 2026

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the ninth annual Cytokinetics Communications Grant Program. The program will award a number of grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) and heart failure communities. The grants are intended to support increased communications, awareness building and community engagement.

“Communications is often an underfunded area of patient